Study Summary
The primary objective of this study is to evaluate the safety and clinical activity of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.
Interested in this trial?
Submit an InquiryInterventions
NKG2D-based CAR T-cellsBIOLOGICAL
Autologous genetically modified anti-NKG2DLs CAR transduced T cells
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Affiliated hospital of jiujiang university | Jiujiang | Jiangxi | China |